152051-61-1
Chemical Structure
bFGF (119-126)
- CAS No.: 152051-61-1
- Formula:C44H76N14O12
- Molecular Weight:993.16
SMILES: OC(C=C1)=CC=C1C[C@H](NC([C@H](CCC(N)=O)NC(CNC([C@H]([C@H](O)C)NC([C@H](CCCNC(N)=N)NC([C@@H](N)CCCCN)=O)=O)=O)=O)=O)C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CC(C)C)=O)=O
Biological Activity: bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
bFGF (119-126) | 99.93% | bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Terada T, et al. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target. 2006;14(8):536-545. [Content Brief]
- [2]. Wu Y, et al. Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles. Drug Dev Ind Pharm. 2013;39(11):1712-1719. [Content Brief]
- [3]. Allahmoradi H, et al. Anti-tumor and anti-metastatic activity of the FGF2 118-126 fragment dependent on the loop structure. Biochem J. 2022;479(12):1285-1302. [Content Brief]
Keywords
